Marty Makary, 27th Commissioner of the U.S. FDA, shared a post on X:
” It’s time for the FDA to allow more real world evidence in the evaluation of potential cures and treatments. Huge databases (like national cancer registries) hold invaluable insights for drug and medical device developers. But onerous requirements have prevented companies from adding big data to their applications.
Fewer bureaucratic rules = more cures and meaningful treatments. Read more.”
More posts featuring Marty (Martin) Makary on OncoDaily.